1. 内閣府 世界の高齢化率の推移平成30年版高齢社会白書 https://www8.cao.go.jp/kourei/whitepaper/w2018/html/zenbun/s1_1_2.h tml
2. Taro Kojima, Masahiro Akishita, Yumi Kameyama, Kiyoshi Yamaguchi, Hiroshi Yamamoto, Masato Eto, Yasuyoshi Ouchi. High risk of adverse drug reactions in elderly patients taking six or more drugs: Analysis of inpatient database. Geriatr Gerontol Int. 2012;12:761-762
3. 厚生労働省医薬・生活衛生局医薬品審査管理課 「医薬品開発と適正な情報提供のための薬物相互作用ガイドライン」について（薬生薬審発 0723第6号, 平成30年 7月23日） https://www.pmda.go.jp/files/000225191.pdf
4. 厚生労働省 平成29年（2017）人口動態統計（確定数）の概況 https://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei17/dl/11_h7.pdf
5. Renate B Schnabel, Xiaoyan Yin, Philimon Gona, Martin G Larson, Alexa S Beiser, David D McManus, Christopher Newton-Cheh, Steven A Lubitz,Jared W Magnani, Patrick T Ellinor, Sudha Seshadri, Philip A Wolf, Ramachandran S Vasan, Emelia J Benjamin, Daniel Levy. 50 year trends in atrial fi brillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study:a cohort study. Lancet. 2015;386:154-162.
6. Ayodele Odutayo, Christopher X Wong, Allan J Hsiao, Sally Hopewell, Douglas G Altman, Connor A Emdin. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ. 2016;354: i4482
7. Vesell ES, Shively CA. Liquid chromatographic assay of warfarin: similarity of warfarin half- lives in human subjects. Science. 1974; 184: 466-468
8. J Crooks, K O'Malley, I H Stevenson. Pharmacokinetics in the elderly. Clin Pharmacokinet. 1976; 1:280-296.
9. Kaminsky L.S., Zhang Z.Y. Human P450 metabolism of warfarin. Pharmacol Ther. 1997; 73: 67-74.
10. Jack Ansell, Jack Hirsh, Leon Poller, Henry Bussey, Alan Jacobson, Elaine Hylek. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest.2004; 126: 204S-233S
11. Karlson B, Leijd B, Hellström K. On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment. Acta Med Scand. 1986; 220: 347-350
12. Clark NP, Delate T, Riggs CS, Witt DM, Hylek EM, Garcia DA, Ageno W, Dentali F, Crowther MA. Warfarin interactions with antibiotics in the ambulatory care setting. JAMA Intern Med. 2014; 174: 409-416
13. Rolf Burghaus, Katrin Coboeken, Thomas Gaub, Lars Kuepfer, Anke Sensse, Hans-Ulrich Siegmund, Wolfgang Weiss, Wolfgang Mueck, Joerg Lippert. Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation. Plos One. 2011; 6: e17626
14. Yugo Yamashita, Ryuji Uozumi, Yasuhiro Hamatani, Masahiro Esato, Yeong-Hwa Chun, Hikari Tsuji, Hiromichi Wada, Koji Hasegawa, Hisashi Ogawa, Mitsuru Abe, Satoshi Morita, Masaharu Akao. Current Status and Outcomes of Direct Oral Anticoagulant Use in Real- World Atrial Fibrillation Patients - Fushimi AF Registry. Circ J. 2017; 81: 1278-1285
15. Patrick C Souverein, Hendrika A van den Ham, Consuelo Huerta, Elisa Martín Merino, Dolores Montero, Luz M León-Muñoz, Sven Schmiedl, Andreas Heeke, Marietta Rottenkolber, Morten Andersen, Mia Aakjaer, Marie L De Bruin, Olaf H Klungel, Helga Gardarsdottir. Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation. Br J Clin Pharmacol. 2020 Jul 6. Doi: 10.1111/bcp.14450. Online ahead of print.
16. Yana Vinogradova, Carol Coupland, Trevor Hill, Julia Hippisley-Cox. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018;362:k2505.
17. Vic Hasselblad, Wendy Gattis Stough, Monica R. Shah, Yuliya Lokhnygina, Christopher M. O’Connor, Robert M. Califf, Kirkwood F. Adams Jr. Relation Between Dose of Loop Diuretics and Outcomes in a Heart Failure Population: Results of the ESCAPE Trial. Eur J Heart Fail. 2007; 10: 1064-1069.
18. Alan S Go, Glenn M Chertow, Dongjie Fan, Charles E McCulloch, Chi- yuan Hsu. Chronic kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization. N Engl J Med. 2004; 351: 1296-1305.
19. Teruhiko Imamura, Koichiro Kinugawa. Tolvaptan Improves the Long-Term Prognosis in Patients With Congestive Heart Failure With Preserved Ejection Fraction as Well as in Those With Reduced Ejection Fraction. Int Heart J. 2016; 57: 600-606.
20. Masayuki Furukawa, Ken Umehara, Eiji Kashiyama. Nonclinical pharmacokinetics of a new nonpeptide V2 receptor antagonist, tolvaptan. Cardiovasc Drugs Ther. 2011; Suppl 1:S83-S89.
21. Susan E Shoaf, Suresh Mallikaarjun. Pharmacokinetic and Pharmacodynamic Interaction Between Tolvaptan and Warfarin in Healthy Subjects. Clin Pharmacol Drug Dev. 2012; 2: 67-75.
22. Kim SR, Hasunuma T, Sato O, Okada T, Kondo M, Azuma J. Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers. Cardiovasc Drugs Ther. 2011; Suppl 1:S5-S17.
23. Jia-Rong Wu, Terry A. Lennie, Rebecca L. Dekker, Martha J. Biddle, Debra K. Moser. Medication Adherence, Depressive Symptoms, and Cardiac Event-Free Survival in Patients with Heart Failure. J Card Fail. 2013; 19:317-324.
24. A Sadik, M. Yousif, J.C. McElnay. Pharmaceutical care of patients with heart failure. Br J Clin Pharmacol. 2005; 60: 183-193.
25. 大塚製薬株式会社医薬品製造販売承認申請書添付資料生物薬剤学及び関連する分析法の概要
26. Herman D., Locatelli I., Grabnar I., Peternel P., Stegnar M., Lainscak M., Mrhar A.,Breskvar K., Dolzan V. The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose. Eur J Clin Pharmacol. 2006; 62: 291-296.
27. Sellers E.M., Koch-Weser J. Displacement of warfarin from human albumin by diazoxide and ethacrynic, mefenamic, and nalidixic acids. Clin Pharmacol Ther. 1970; 11: 524-529
28. Wong L.T., Solomonraj G., Thomas B.H. Fate of [14C] warfarin in guinea-pigs: effect of a concomitant single dose of salicylate. J Pharm Pharmacol. 1978; 30: 240-243.
29. Saito M., Ajioka M., Iwao T., Suzuki T. Enhancement of warfarin anticoagulant reaction in patients with repeated oral tolvaptan administration. Biol Pharm Bull. 2018; 41: 1014-1016.
30. Radwan M.A., Bawazeer G.A., Aloudah N.M., AIQuadeib B.T., Aboul- Enein H.Y. Determination of free and total warfarin concentrations in plasma using UPLC MS/MS and its application to a patient samples. Biomed Chromatogr. 2012; 26: 6-11.
31. Rimac H., Dufour C., Debeljak Ž., Zorc B., Bojić M. Warfarin and Flavonoids Do Not Share the Same Binding Region in Binding to the IIA Subdomain of Human Serum Albumin. Molecules. 2017; 22:1153.
32. S Y King, M A Joslin, K Raudibaugh, H J Pieniaszek Jr, I H Benedek. Dose-dependent pharmacokinetics of warfarin in healthy volunteers. Pharm Res. 1995; 12: 1874-1877.
33. Robert A O'Reilly., P M Aggeler. Studies on coumarin anticoagulant drugs. Initiation of warfarin therapy without a loading dose. Circulation. 1968; 38: 169-177.
34. Rolan P.E. Plasma protein binding displacement interactions--why are they still regarded as clinically important? Br J Clin Pharmacol. 1994; 37: 125-128.
35. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest. 2005; 127: 2049-2056.
36. Bhatt P.R., McNeely E.B., Lin T.E., Adams K.F., Patterson J.H. Review of Tolvaptan's Pharmacokinetic and Pharmacodynamic Properties and Drug Interactions. J Clin Med. 2014; 3: 1276-1290.
37. Durability of class I American College of Cardiology/American Heart Association clinical practice guideline recommendations. JAMA. 2014; 311: 2092-2100.
論文の公開元へ
